The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990–2019: a population-based study

Yi Feng Wen, Mengxuan Chen, Guosheng Yin, Ruitao Lin, Yu Jie Zhong, Qian Dong, Hai Ming WongJournal of Hematology & Oncology 2021 · DOI

Abstract

The global burden of AYA cancers is substantial and disproportionally affect populations in limited-resource settings. Capacity building for AYA cancers is essential in promoting equity and population health worldwide.

Introduction

Adolescents and young adults (AYAs), defined as individuals aged 15–39, represent a unique demographic in oncology. Often overlooked in favor of pediatric or geriatric research, this group faces distinct biological and psychosocial challenges. This study provides a comprehensive global mapping of the AYA cancer burden over three decades, utilizing data from 204 countries to highlight critical gaps in care and equity.

The AYA "Care Gap"

Cancer research and policy typically focus on the extremes of the age spectrum. AYAs fall into a "care gap," characterized by unique tumor types, lower clinical trial enrollment, and social hurdles such as high uninsured rates. Unlike older adults, a cancer diagnosis in a 25-year-old threatens decades of potential life and productivity. To capture this impact, this study emphasizes Disability-Adjusted Life Years (DALYs)—a metric combining years of life lost (YLLs) to premature death with years lived with disability (YLDs).

Methodology and Data Sources

Researchers employed the Global Burden of Disease (GBD) 2019 study framework, managed by the Institute for Health Metrics and Evaluation (IHME). The analysis included:

  • Metrics: Calculation of incidence, mortality, YLDs, YLLs, and DALYs.
  • Standardization: Truncated age-standardized rates were calculated for the 15–39 cohort to ensure cross-regional comparability.
  • Socio-demographic Analysis: LOWESS regression was used to explore the relationship between the Socio-demographic Index (SDI) and cancer burden.
  • Data Inputs: Mortality data were sourced from vital registration systems and verbal autopsies, while incidence data came from high-quality cancer registries.

In 2019, the global AYA cancer burden reached 1.19 million incident cases, 396,000 deaths, and 23.5 million DALYs. While global incidence rates increased by 10.7% between 1990 and 2019, death rates decreased by 21%, indicating general progress in treatment. However, these gains are not uniform.

Regional variations in AYA cancer incidence, mortality, and DALY rates (a-c), and their percentage changes from 1990 to 2019 (d-f).

As shown in the figure above, Western Europe exhibits the highest incidence rates, yet regions like Oceania and sub-Saharan Africa suffer the highest mortality and DALY rates. This highlights a stark "equity gap": high-income countries diagnose more cases, but low- and middle-income countries (LMICs) bear a disproportionate share of the actual suffering and death. Notably, 97.3% of the global DALY burden for AYAs stems from premature death (YLLs).

Key Insights: The Gender and Socio-economic Divide

  • The Female Burden: Incidence is significantly higher in females, primarily driven by breast and cervical cancers. Breast cancer remains the leading cause of AYA cancer deaths and DALYs globally.
  • The "Inverted U" of SDI: A paradoxical relationship exists between development and cancer burden. While incidence rises with SDI (due to better screening), mortality and DALY rates follow an inverted U-shape, peaking in middle-SDI countries that may lack the specialized infrastructure to manage AYA-specific malignancies effectively.
  • Relative Impact: Globally, AYA cancers are the second leading cause of death among non-communicable diseases for this age group. In low-SDI regions, the AYA cancer DALY burden actually ranks first when compared to childhood and older adult cancers.

Limitations and Future Directions

The study is limited by data sparsity in low-income regions, potentially leading to underestimations of incidence. Furthermore, the GBD's topography-based coding may not fully capture AYA-specific conditions like Kaposi sarcoma.

Future efforts must focus on capacity building in LMICs, improving surveillance systems, and integrating AYA-specific research into clinical pathways. Addressing treatment-refractory tumors and long-term toxicity is essential to closing the global equity gap in AYA cancer care.

Summary updated

Abstract

The global burden of AYA cancers is substantial and disproportionally affect populations in limited-resource settings. Capacity building for AYA cancers is essential in promoting equity and population health worldwide.
BibTeX
@article{wen2021global,
  author = {Yi Feng Wen and Mengxuan Chen and Guosheng Yin and Ruitao Lin and Yu Jie Zhong and Qian Dong and Hai Ming Wong},
  title = {{The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990–2019: a population-based study}},
  journal = {Journal of Hematology \& Oncology},
  year = {2021},
  doi = {10.1186/s13045-021-01093-3},
}
Figure